← Back to patent-cliff list
Sulopenem etzadroxil/Probenecid
Tier C — Watch / tradeSulopenem etzadroxil/Probenecid
Pfizer Inc.
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CYP2C9
Brand：Orlynvah
Indications (approved)：Urinary tract infection
Regional status
US
Approved
2024-10-25
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sulopenem etzadroxil/Probenecid?
Approved indications include: Urinary tract infection.
When does the Sulopenem etzadroxil/Probenecid patent expire?
No public expiry year is available for Sulopenem etzadroxil/Probenecid yet; this page updates once verified.
How do I get a quote for Sulopenem etzadroxil/Probenecid intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01